Literature DB >> 21540025

C5b-9-activated, K(v)1.3 channels mediate oligodendrocyte cell cycle activation and dedifferentiation.

Cosmin A Tegla1, Cornelia Cudrici, Monika Rozycka, Katerina Soloviova, Takahiro Ito, Anil K Singh, Aamer Khan, Philippe Azimzadeh, Maria Andrian-Albescu, Anver Khan, Florin Niculescu, Violeta Rus, Susan I V Judge, Horea Rus.   

Abstract

Voltage-gated potassium (K(v)) channels play an important role in the regulation of growth factor-induced cell proliferation. We have previously shown that cell cycle activation is induced in oligodendrocytes (OLGs) by complement C5b-9, but the role of K(v) channels in these cells had not been investigated. Differentiated OLGs were found to express K(v)1.4 channels, but little K(v)1.3. Exposure of OLGs to C5b-9 modulated K(v)1.3 functional channels and increased protein expression, whereas C5b6 had no effect. Pretreatment with the recombinant scorpion toxin rOsK-1, a highly selective K(v)1.3 inhibitor, blocked the expression of K(v)1.3 induced by C5b-9. rOsK-1 inhibited Akt phosphorylation and activation by C5b-9 but had no effect on ERK1 activation. These data strongly suggest a role for K(v)1.3 in controlling the Akt activation induced by C5b-9. Since Akt plays a major role in C5b-9-induced cell cycle activation, we also investigated the effect of inhibiting K(v)1.3 channels on DNA synthesis. rOsK-1 significantly inhibited the DNA synthesis induced by C5b-9 in OLG, indicating that K(v)1.3 plays an important role in the C5b-9-induced cell cycle. In addition, C5b-9-mediated myelin basic protein and proteolipid protein mRNA decay was completely abrogated by inhibition of K(v)1.3 expression. In the brains of multiple sclerosis patients, C5b-9 co-localized with NG2(+) OLG progenitor cells that expressed K(v)1.3 channels. Taken together, these data suggest that K(v)1.3 channels play an important role in controlling C5b-9-induced cell cycle activation and OLG dedifferentiation, both in vitro and in vivo.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21540025      PMCID: PMC3139709          DOI: 10.1016/j.yexmp.2011.04.006

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  44 in total

1.  Lack of replicative senescence in cultured rat oligodendrocyte precursor cells.

Authors:  D G Tang; Y M Tokumoto; J A Apperly; A C Lloyd; M C Raff
Journal:  Science       Date:  2001-01-18       Impact factor: 47.728

2.  Complement mediated cell death is associated with DNA fragmentation.

Authors:  M S Cragg; W J Howatt; L Bloodworth; V A Anderson; B P Morgan; M J Glennie
Journal:  Cell Death Differ       Date:  2000-01       Impact factor: 15.828

3.  Proliferating oligodendrocytes are present in both active and chronic inactive multiple sclerosis plaques.

Authors:  M Solanky; Y Maeda; X Ming; W Husar; W Li; S Cook; P Dowling
Journal:  J Neurosci Res       Date:  2001-08-15       Impact factor: 4.164

4.  Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination.

Authors:  C Lucchinetti; W Brück; J Parisi; B Scheithauer; M Rodriguez; H Lassmann
Journal:  Ann Neurol       Date:  2000-06       Impact factor: 10.422

5.  Inhibition of oligodendrocyte apoptosis by sublytic C5b-9 is associated with enhanced synthesis of bcl-2 and mediated by inhibition of caspase-3 activation.

Authors:  L Soane; H Rus; F Niculescu; M L Shin
Journal:  J Immunol       Date:  1999-12-01       Impact factor: 5.422

6.  C5b-9 terminal complement complex protects oligodendrocytes from death by regulating Bad through phosphatidylinositol 3-kinase/Akt pathway.

Authors:  L Soane; H J Cho; F Niculescu; H Rus; M L Shin
Journal:  J Immunol       Date:  2001-08-15       Impact factor: 5.422

7.  Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.

Authors:  Andrew D Goodman; Theodore R Brown; Lauren B Krupp; Randall T Schapiro; Steven R Schwid; Ron Cohen; Lawrence N Marinucci; Andrew R Blight
Journal:  Lancet       Date:  2009-02-28       Impact factor: 79.321

Review 8.  Sustained-release fampridine for multiple sclerosis.

Authors:  Christopher T Bever; Susan Iv Judge
Journal:  Expert Opin Investig Drugs       Date:  2009-07       Impact factor: 6.206

9.  Response gene to complement 32 is required for C5b-9 induced cell cycle activation in endothelial cells.

Authors:  Matthew Fosbrink; Cornelia Cudrici; Cosmin A Tegla; Kateryna Soloviova; Takahiro Ito; Sonia Vlaicu; Violeta Rus; Florin Niculescu; Horea Rus
Journal:  Exp Mol Pathol       Date:  2009-01-07       Impact factor: 3.362

Review 10.  Axonal control of oligodendrocyte development.

Authors:  B A Barres; M C Raff
Journal:  J Cell Biol       Date:  1999-12-13       Impact factor: 10.539

View more
  15 in total

1.  Activation of endogenously expressed ion channels by active complement in the retinal pigment epithelium.

Authors:  Andreas Genewsky; Ingmar Jost; Catharina Busch; Christian Huber; Julia Stindl; Christine Skerka; Peter F Zipfel; Bärbel Rohrer; Olaf Strauß
Journal:  Pflugers Arch       Date:  2014-11-27       Impact factor: 3.657

Review 2.  The Role of the Oligodendrocyte Lineage in Acute Brain Trauma.

Authors:  Anja Scheller; Xianshu Bai; Frank Kirchhoff
Journal:  Neurochem Res       Date:  2017-07-12       Impact factor: 3.996

3.  Oligodendrocytes control potassium accumulation in white matter and seizure susceptibility.

Authors:  Valerie A Larson; Yevgeniya Mironova; Kimberly G Vanderpool; Ari Waisman; John E Rash; Amit Agarwal; Dwight E Bergles
Journal:  Elife       Date:  2018-03-29       Impact factor: 8.140

4.  A Kv1.3 channel-specific blocker alleviates neurological impairment through inhibiting T-cell activation in experimental autoimmune encephalomyelitis.

Authors:  Xiao-Lu Yuan; Yi-Peng Zhao; Jie Huang; Jun-Chen Liu; Wen-Qian Mao; Jun Yin; Bi-Wen Peng; Wan-Hong Liu; Song Han; Xiao-Hua He
Journal:  CNS Neurosci Ther       Date:  2018-03-25       Impact factor: 5.243

5.  Human immunodeficiency virus protein Tat induces oligodendrocyte injury by enhancing outward K+ current conducted by KV1.3.

Authors:  Han Liu; Jianuo Liu; Enquan Xu; Guihua Tu; Minglei Guo; Shangdong Liang; Huangui Xiong
Journal:  Neurobiol Dis       Date:  2016-11-02       Impact factor: 5.996

Review 6.  Membrane attack by complement: the assembly and biology of terminal complement complexes.

Authors:  Cosmin A Tegla; Cornelia Cudrici; Snehal Patel; Richard Trippe; Violeta Rus; Florin Niculescu; Horea Rus
Journal:  Immunol Res       Date:  2011-10       Impact factor: 2.829

7.  Cd59 and inflammation regulate Schwann cell development.

Authors:  Ashtyn T Wiltbank; Emma R Steinson; Stacey J Criswell; Melanie Piller; Sarah Kucenas
Journal:  Elife       Date:  2022-06-24       Impact factor: 8.713

Review 8.  The complement system as a biomarker of disease activity and response to treatment in multiple sclerosis.

Authors:  Alexandru Tatomir; Anamaria Talpos-Caia; Freidrich Anselmo; Adam M Kruszewski; Dallas Boodhoo; Violeta Rus; Horea Rus
Journal:  Immunol Res       Date:  2017-12       Impact factor: 2.829

9.  Unconventional EGF-induced ERK1/2-mediated Kv1.3 endocytosis.

Authors:  Ramón Martínez-Mármol; Núria Comes; Katarzyna Styrczewska; Mireia Pérez-Verdaguer; Rubén Vicente; Lluís Pujadas; Eduardo Soriano; Alexander Sorkin; Antonio Felipe
Journal:  Cell Mol Life Sci       Date:  2015-11-05       Impact factor: 9.261

Review 10.  Neuron-NG2 cell synapses: novel functions for regulating NG2 cell proliferation and differentiation.

Authors:  Qian-Kun Yang; Jia-Xiang Xiong; Zhong-Xiang Yao
Journal:  Biomed Res Int       Date:  2013-08-01       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.